NVCR - ノボキュア （NovoCure Limited） ノボキュアNVCRのチャート
NVCRの企業情報
| symbol | NVCR |
|---|---|
| 会社名 | NovoCure Ltd （ノボキュア） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ノボキュア(NovoCure Limited)は商業段階の腫瘍学会社である。同社は固形癌細胞分裂を破壊するために特定の周波数に調整された電場を使用するTTFieldsと呼ばれる療法を中心とする癌治療法の開発に従事する。TTFieldsはグリア芽腫（GBM）の治療に使用され、臨床パイプラインを通じて複数の固形腫瘍適応症におけるTTFieldのプログラム検査を進めるために使用される。GBMの臨床的・商業的発展に加えて、TTFieldは脳転移、非小細胞肺癌（NSCLC）、膵臓癌、卵巣癌および中皮腫におけるTTFieldの使用を評価する臨床試験を計画または実施している。TTFieldは、ポータブルな医療機器を通じて提供される。完全な送達システムは、継続的な癌治療を受けながら患者が日々の活動に慣れることができるように設計され、携帯用電界ジェネレータ、トランスデューサアレイ、充電式バッテリ、アクセサリーを含む。 ノボキュアは英国の医療機器メ―カ―。主に固形がん腫瘍の治療向け医療機器の開発に従事する。同社開発の「TTFields」は非侵襲性の腫瘍治療電場システムで、細胞分裂阻止の治療電場を発生させ通常のプロセスを阻害し、がん細胞を死滅する。一般的ながん治療である手術、放射線治療、抗がん剤治療に合わせ、更なる治療法を開発する。本社は英国ジャ―ジ―島。 Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. |
| 本社所在地 | No. 4 The Forum Grenville Street St. Helier Jersey JE2 4UF GBR |
| 代表者氏名 | William F. Doyle ウィリアムF.ドイル |
| 代表者役職名 | Executive Chairman of the Board 取締役会長 |
| 電話番号 | +44 1534-75-6700 |
| 設立年月日 | 36557 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 495人 |
| url | www.novocure.com |
| nasdaq_url | https://www.nasdaq.com/symbol/nvcr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -21.49100 |
| 終値（lastsale） | 48.2 |
| 時価総額（marketcap） | 4477903392 |
| 時価総額 | 時価総額（百万ドル） 3966.939 |
| 売上高 | 売上高（百万ドル） 217.40900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 3897.179 |
| 当期純利益 | 当期純利益（百万ドル） -93.47700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Novocure Ltd revenues increased 55% to $113.6M. Net loss decreased 8% to $36.2M. Revenues reflect Europe_Middle East_Africa (EMEA) (Region) segment increase from $12.6M to $32.4M United States segment increase of 32% to $79.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.45 to -$0.40. |
NVCRのテクニカル分析
NVCRのニュース
Novocure to Report First Quarter 2023 Financial Results 2023/04/03 12:00:00 Business Wire
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure announced today that it will report financial results for the first quarter 2023 on May 4, 2023, before the U.S. financial markets open.
NovoCure Stock: Pipeline Conversion Is Key (NASDAQ:NVCR) 2023/03/27 09:22:43 Seeking Alpha
NovoCure has seen strong growth over the past decade but unable to post profits with large sums invested into the pipeline. Read why NVCR stock is a Buy.
Exploring The Potential Of NovoCure''s TTFields In Non-Small Cell Lung Cancer 2023/03/20 19:02:25 Seeking Alpha
NovoCure focuses on promoting Optune and Optune Lua, utilizing TTFields technology to target and destroy cancer cells. See why we recommend a buy on NVCR stock.
JPMorgan Downgrades NovoCure Ltd. to Underweight 2023/03/17 10:01:06 Investing.com
https://www.investing.com/news/pro/jpmorgan-downgrades-novocure-ltd-to-underweight-432SI-3033169
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program 2023/03/16 11:30:00 Business Wire
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.
Novocure to Participate in Upcoming Investor Conferences 2022/08/31 12:00:00 Wallstreet:Online
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will participate in the 2022 Wells Fargo Healthcare Conference on September 7, 2022. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 4:20 p.m. EDT, as well as one-on-one meetings with investors
Why I Own Novocure Stock (NVCR) 2022/08/22 14:15:00 The Motley Fool
Motley Fool contributor Brian Orelli shares why he loves this stock
NovoCure Earnings Perspective: Return On Capital Employed 2022/08/04 14:23:56 Benzinga
NovoCure (NASDAQ: NVCR ) brought in sales totaling $140.87 million during Q2 according to data provided by Benzinga Pro . However, earnings decreased 416.63%, resulting in a loss of $24.01 million. In Q1, NovoCure brought in $137.55 million in sales but lost $4.65 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and … Full story available on Benzinga.com
NovoCure Stock: Valuations Are Unattractive Despite Good Q2 2022/07/29 17:09:34 Seeking Alpha
NovoCure printed another successful quarter, but came in behind consensus below the bottom line. See why we are bullish on NVCR stock for long-term.
NovoCure Ltd. PT Lowered to $105 at Truist Securities 2022/07/29 12:11:17 Investing.com
https://www.investing.com/news/pro/novocure-ltd-pt-lowered-to-105-at-truist-securities-432SI-2858107
NovoCure Limited (NASDAQ:NVCR) Is 22.21% Above Its 52-Week Low, But How Long Can It Continue? 2022/04/30 12:00:00 Marketing Sentinel
In last trading session, NovoCure Limited (NASDAQ:NVCR) saw 0.65 million shares changing hands with its beta currently measuring 0.85. Company’s recent per share price level of $76.58 trading at -$0.6 or -0.78% at ring of the bell on the day assigns it a market valuation of $8.58B. That closing price of NVCR’s stock is at … NovoCure Limited (NASDAQ:NVCR) Is 22.21% Above Its 52-Week Low, But How Long Can It Continue? Read More »
Novocure (NVCR) Q1 2022 Earnings Call Transcript 2022/04/28 17:30:35 The Motley Fool
NVCR earnings call for the period ending March 31, 2022.
NovoCure Limited''s (NVCR) Management on Q1 2022 Results - Earnings Call Transcript 2022/04/28 16:30:26 Seeking Alpha
NovoCure Limited (NASDAQ:NASDAQ:NVCR) Q1 2022 Earnings Conference Call April 28, 2022 8:00 AM ET Company Participants Ingrid Goldberg – Investor Relations Bill Doyle – Executive Chairman…
NovoCure: Q1 Earnings Insights 2022/04/28 13:54:48 Benzinga
NovoCure (NASDAQ: NVCR ) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings NovoCure beat estimated earnings by 77.78%, reporting an EPS of $-0.04 versus an … Full story available on Benzinga.com